PSTV furnishes Q3 2025 results via Exhibit 99.1 press release

Rhea-AI Filing Summary

Plus Therapeutics (PSTV) filed an 8-K stating it reported financial results for the third quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1, which is incorporated by reference.

The disclosure under Item 2.02 is furnished, not filed, under the Exchange Act. This routine update provides access to the company’s Q3 2025 results through the attached press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000109598100010959812025-10-302025-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

PLUS THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-34375	33-0827593
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2710 REED ROAD Suite 160
Houston, Texas				77051
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (737) 255-7194

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		PSTV		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Item 2.02 Results of Operations and Financial Condition.

On October 30, 2025, Plus Therapeutics, Inc. (the “Company”) reported financial results for the third quarter ended September 30, 2025 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit Number		Description
99.1		Press Release Announcing Financial Results, dated October 30, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PLUS THERAPEUTICS, INC.
Date:	October 30, 2025	By:	/s/ Marc H. Hedrick, M.D.
			Marc H. Hedrick, M.D. President and Chief Executive Officer

FAQ

What did PSTV announce in its 8-K?

The company reported financial results for the third quarter ended September 30, 2025, and furnished a press release as Exhibit 99.1.

Which period does the PSTV update cover?

It covers the third quarter ended September 30, 2025.

Where can I find the detailed Q3 2025 results for PSTV?

Details are in the press release furnished as Exhibit 99.1 to the 8-K.

Is the PSTV Q3 2025 information filed or furnished?

The information in Item 2.02, including Exhibit 99.1, is furnished, not filed, under the Exchange Act.

What is PSTV’s trading symbol and exchange?

The trading symbol is PSTV on The Nasdaq Capital Market.

Who signed the PSTV 8-K?

It was signed by Marc H. Hedrick, M.D., President and Chief Executive Officer.